Medindia

X

The Launch of Eight Novel Disease-Modifying Therapies, Including the First Oral Agents Approved for the Indication, Will Drive Modest Growth in the Multiple Sclerosis Drug Market Through 2019

Monday, July 12, 2010 Drug News J E 4
Advertisement
Novartis/Mitsubishi Tanabe Pharma's FTY-720 and Merck Serono/EMD Serono's Oral Cladribine Will Have the Most Significant Market Impact, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Poised for Medicare Market Success, Humana to Face...
S
Althea Technologies Chooses Blue Mountain Regulato...